Milagen, Inc.

Emeryville, CA 94608

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.23MM
First Award Date 09/15/05
Most Recent Award Date 07/01/09

Key Personnel

Last Name Name Awards Contact
Valle Rosaura P.C. Valle 3
Chavany Christine Chavany 2

5 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 07/01/09 - 06/30/10

DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma (PaC) is the fourth-leading cause of cancer death in the US, with 37,170 estimated new cases for 2007 and almost as many deaths. This high mortality rate is due to the fact that PaC is generally detected at an advanced stage, and there is no screening test available. Detection of cli...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-50
Budget: 09/22/08 - 08/31/09

DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the third most common cancer in both men and women, and accounts for almost 10% of all cancer deaths. There are several recommended screening methods for CRC, including colonoscopy and FOBT. Colonoscopy is the current gold standard, yet it is invasive and expensive, and FOBT is not ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 07/01/08 - 06/30/09

DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma (PaC) is the fourth-leading cause of cancer death in the US, with 37,170 estimated new cases for 2007 and almost as many deaths. This high mortality rate is due to the fact that PaC is generally detected at an advanced stage, and there is no screening test available. Detection of cli...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-06
Budget: 09/12/06 - 02/28/07

DESCRIPTION (provided by applicant): Project Summary/Abstract: Pancreatic adenocarcinoma (PaC) is the fourth-leading cause of cancer death in the US, with 132,180 estimated new cases for 2005 and almost as many deaths. This high mortality rate is due to the fact that PaC is generally detected at an advanced stage, and there is no screening test ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/05 - 03/14/06

DESCRIPTION (provided by applicant): Our ultimate goal is to develop and commercialize new, sensitive, specific, non-invasive and "user-friendly" immunodiagnostic assays based on patients' serum for the early detection of type 2 diabetes. These assays, that would not require fasting or glucose administration, would improve diagnosis, disease pr...